SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SCYNEXIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.66−0.01 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $43.28M
- P/E (TTM)
- –
- Dividend yield
- –
SCYNEXIS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Agreement Revenue | $235.00K | $0 | $17.20M | $334.00K | $1.36M | $257.00K | $977.00K | $660.00K | $736.00K | $1.37M | $5.74M | $2.38M | 100.0% | -82.8% |
| Product Revenue, Net | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $60.00K | -$614.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Scynexis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.